Carroll Financial Associates’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | $2.34M | Buy |
17,394
+1,238
| +8% | +$146K | 0.12% | 108 |
|
|
2021
Q3 | $1.74M | Buy |
16,156
+189
| +1% | +$21.6K | 0.1% | 130 |
|
|
2021
Q2 | $1.8M | Buy |
15,967
+309
| +2% | +$34.8K | 0.1% | 127 |
|
|
2021
Q1 | $1.69M | Sell |
15,658
-529
| -3% | -$56.6K | 0.1% | 124 |
|
|
2020
Q4 | $1.73M | Buy |
16,187
+509
| +3% | +$48.9K | 0.12% | 112 |
|
|
2020
Q3 | $1.37M | Sell |
15,678
-35
| -0.2% | -$3.29K | 0.11% | 120 |
|
|
2020
Q2 | $1.54M | Buy |
15,713
+3,676
| +31% | +$324K | 0.13% | 103 |
|
|
2020
Q1 | $917K | Buy |
12,037
+273
| +2% | +$23.3K | 0.09% | 138 |
|
|
2019
Q4 | $1.04M | Sell |
11,764
-5
| -0% | -$415 | 0.08% | 136 |
|
|
2019
Q3 | $891K | Buy |
11,769
+477
| +4% | +$32.7K | 0.08% | 154 |
|
|
2019
Q2 | $821K | Buy |
11,292
+563
| +5% | +$44.3K | 0.07% | 154 |
|
|
2019
Q1 | $864K | Buy |
10,729
+5,885
| +121% | +$481K | 0.08% | 137 |
|
|
2018
Q4 | $437K | Sell |
4,844
-249
| -5% | -$21.9K | 0.05% | 170 |
|
|
2018
Q3 | $481K | Buy |
5,093
+16
| +0.3% | +$1.52K | 0.05% | 175 |
|
|
2018
Q2 | $470K | Sell |
5,077
-833
| -14% | -$81.4K | 0.05% | 174 |
|
|
2018
Q1 | $559K | Sell |
5,910
-87
| -1% | -$9.56K | 0.06% | 156 |
|
|
2017
Q4 | $580K | Sell |
5,997
-61
| -1% | -$5.75K | 0.06% | 155 |
|
|
2017
Q3 | $546K | Buy |
6,058
+46
| +0.8% | +$3.5K | 0.06% | 147 |
|
|
2017
Q2 | $435K | Buy |
6,012
+1,573
| +35% | +$106K | 0.05% | 173 |
|
|
2017
Q1 | $289K | Buy |
4,439
+35
| +0.8% | +$2.2K | 0.04% | 217 |
|
|
2016
Q4 | $275K | Buy |
4,404
+246
| +6% | +$15K | 0.04% | 206 |
|
|
2016
Q3 | $262K | Buy |
4,158
+247
| +6% | +$16K | 0.04% | 208 |
|
|
2016
Q2 | $242K | Sell |
3,911
-14
| -0.4% | -$853 | 0.04% | 210 |
|
|
2016
Q1 | $224K | Buy |
3,925
+711
| +22% | +$39.6K | 0.04% | 208 |
|
|
2015
Q4 | $190K | Buy |
3,214
+39
| +1% | +$2.25K | 0.04% | 213 |
|
|
2015
Q3 | $170K | Buy |
3,175
+172
| +6% | +$11.2K | 0.04% | 213 |
|
|
2015
Q2 | $202K | Buy |
3,003
+811
| +37% | +$52.9K | 0.05% | 190 |
|
|
2015
Q1 | $128K | Sell |
2,192
-200
| -8% | -$12.1K | 0.06% | 175 |
|
|
2014
Q4 | $136K | Buy |
2,392
+375
| +19% | +$23.6K | 0.09% | 142 |
|
|
2014
Q3 | $128K | Buy |
2,017
+975
| +94% | +$54.1K | 0.04% | 187 |
|
|
2014
Q2 | $59K | Buy |
1,042
+50
| +5% | +$2.62K | 0.02% | 300 |
|
|
2014
Q1 | $51K | Buy |
992
+300
| +43% | +$15.2K | 0.02% | 301 |
|
|
2013
Q4 | $36K | Sell |
692
-250
| -27% | -$12.3K | 0.01% | 325 |
|
|
2013
Q3 | $42K | Sell |
942
-100
| -10% | -$4.43K | 0.02% | 309 |
|
|
2013
Q2 | $43K | Buy |
+1,042
| New | +$45.6K | 0.02% | 249 |
|
Other funds holding ABBV
Carroll Financial Associates's ABBV Position: Q4 2021 in Review
Carroll Financial Associates increased its AbbVie (ABBV) stake by 7.7% in Q4 2021, buying an estimated $146K and bringing the position to 17,394 shares worth $2.34M. The position accounts for 0.12% of the portfolio, ranked #108.
Carroll Financial Associates first reported a position in ABBV in Q2 2013 and has held it in 35 quarters since. 2,981 funds tracked by Wall St. Rank hold ABBV as of Q4 2021.
- Carroll Financial Associates held 17,394 shares of AbbVie worth $2.34M as of Q4 2021.
- Carroll Financial Associates bought 1,238 AbbVie shares in Q4 2021, an estimated $146K.
- AbbVie made up 0.12% of Carroll Financial Associates's portfolio in Q4 2021, its #108 holding.
- Carroll Financial Associates first reported a position in AbbVie in Q2 2013 and has held it in 35 quarters since.
- 2,981 funds tracked by Wall St. Rank held AbbVie as of Q4 2021.
Based on Carroll Financial Associates's 13F filing for Q4 2021, filed 6 Jan 2022.